SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Currently, Praveen Akkinepally is the Head of Lung Cancer Commercialization, AstraZeneca Gaithersburg, MD, USA
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Subscribe To Our Newsletter & Stay Updated